Traws Pharma (TRAW) Stock Price, News & Analysis

Company Overview

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Key Stats

• Today's Range: $1.49 to $1.57
• 50-Day Range: $1.38 to $1.87
• 52-Week Range: $0.97 to $19.44
• Volume: 19,932 shs
• Average Volume: 68,009 shs
• Market Capitalization: $8.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TRAW Stock Analysis - Frequently Asked Questions

How have TRAW shares performed this year?

Traws Pharma's stock was trading at $8.88 at the start of the year. Since then, TRAW stock has decreased by 82.9% and is now trading at $1.52.

How were Traws Pharma's earnings last quarter?

Traws Pharma, Inc. (NASDAQ:TRAW) released its quarterly earnings data on Thursday, May, 15th. The company reported $2.09 earnings per share (EPS) for the quarter, topping the consensus estimate of ($8.04) by $10.13. The firm earned $0.06 million during the quarter, compared to analyst estimates of $0.06 million.

How do I buy shares of Traws Pharma?

Shares of TRAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Traws Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Traws Pharma investors own include Clearside Biomedical (CLSD), Evofem Biosciences (EVFM), Palatin Technologies (PTN), Sirius XM (SIRI), Adverum Biotechnologies (ADVM) and Aptinyx (APTX).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 8/06/2025
• Next Earnings (Estimated): 8/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TRAW
• Previous Symbol: NASDAQ:TRAW
• CIK: 1130598
• Web: www.onconova.com
• Phone: 267-759-3680
• Fax: 267-759-3681
• Employees: 17
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($32.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$166.52 million
• Net Margins: -15,245.81%
• Pretax Margin: -61,696.04%
• Return on Equity: N/A
• Return on Assets: -193.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.81
• Quick Ratio: 1.81

Sales & Book Value

• Annual Sales: $230 thousand
• Price / Sales: 36.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($8.66) per share
• Price / Book: -0.18

Miscellaneous

• Outstanding Shares: 5,560,000
• Free Float: 4,807,000
• Market Cap: $8.45 million
• Optionable: Optionable
• Beta: 1.14